Citations

Showing 10 of 108152 citations.

Brachial Plexus Birth Injuries
Pulos, Nicholas , Shaughnessy, William J. , Spinner, Robert J. , Shin, Alexander Y. , Shin, Alexander Y , Pulos, Nicholas

Mayo Clinic

JBJS Reviews | June 8, 2021 | Volume: 9 | Issue: 6 | Pages: No page available

10.2106/jbjs.rvw.20.00004 | PMID 34102666 Get It

» The incidence of brachial plexus birth injury (BPBI) in the United States is declining and now occurs in <1 per 1,000 births. » The gold standard for predicting the need for early intervention remains serial examination. » Early treatment of BPBI with reconstructive surgery requires the ability to perform both interposition nerve grafting and nerve transfers. » Given the heterogeneity of lesions, the evidence is largely limited to retrospective comparative studies and case series.
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia
Bendig, Sonja , Gu, Zhaohui , Chen, Xiaolong , Ma, Xiaotu , Murison, Alex, Zeng, Andy G.X. , Dickerson, Kirsten , Mead, Paul E., Mehr, Cyrus M., Xu, Beisi , Cheng, Zhongshan , Chang, Ti‐Cheng , Westover, Tamara , Ma, Jing , Stengel, Anna , Kimura, Shunsuke , Valentine, Marcus B., Rashkovan, Marissa , Luger, Selina M. , Litzow, Mark R. , Rowe, Jacob M. , Wang, Victoria , Yin, Jun , Loh, Mignon L. , Crews, Kristine R. , Relling, Mary V. , Evans, William E. , Paietta, Elisabeth , Ferrando, Adolfo A. , Zhang, Jinghui , Kern, Wolfgang , Haferlach, Torsten , Dick, John E. , Klco, Jeffery M. , Gu, Zhaohui , Chen, Xiaolong , Ma, Xiaotu , Abdelhamed, Sherif , Xu, Beisi , Kimura, Shunsuke , Rashkovan, Marissa , den Boer, Monique L , Yin, Jun , Hunger, Stephen P , Pui, Ching-Hon , Yang, Wenjian , Crews, Kristine R , Roberts, Kathryn G , Stock, Wendy , Zhang, Jinghui , Dick, John E , Klco, Jeffery M , Mullighan, Charles G , Loh, Mignon L , Kern, Wolfgang , Montefiori, Lindsey E. , Pölönen, Petri , García‐Prat, Laura , Iacobucci, Ilaria , Hiltenbrand, Ryan , Qu, Chunxu , Kornblau, Steven M. , Hunger, Stephen P. , Yang, Wenjian , Roberts, Kathryn G. , Yang, Jun J.J. , Stock, Wendy , Wu, Gang , Haferlach, Claudia , Mullighan, Charles G.

Mayo Clinic

Cancer Discovery | June 8, 2021 | Volume: 11 | Issue: 11 | Pages: 2846-2867

10.1158/2159-8290.cd-21-0145 | PMID 34103329 Get It

Abstract Lineage-ambiguous leukemias are high-risk malignancies of poorly understood genetic basis. Here, we describe a distinct subgroup of acute leukemia with expression of myeloid, T lymphoid, and stem cell markers driven by aberrant allele-specific deregulation of BCL11B, a master transcription factor responsible for thymic T-lineage commitment and specification. Mechanistically, this deregulation was driven by chromosomal rearrangements that juxtapose BCL11B to superenhancers active in hematopoietic progenitors, or focal amplifications that generate a superenhancer from a noncoding element distal to BCL11B. Chromatin conformation analyses demonstrated long-range interactions of rearranged enhancers with the expressed BCL11B allele and association of BCL11B with activated hematopoietic progenitor cell cis-regulatory elements, suggesting BCL11B is aberrantly co-opted into a gene regulatory network that drives transformation by maintaining a progenitor state. These data support a role for ectopic BCL11B expression in primitive hematopoietic cells mediated by enhancer hijacking as an oncogenic driver of human lineage-ambiguous leukemia. Significance: Lineage-ambiguous leukemias pose significant diagnostic and therapeutic challenges due to a poorly understood molecular and cellular basis. We identify oncogenic deregulation of BCL11B driven by diverse structural alterations, including de novo superenhancer generation, as the driving feature of a subset of lineage-ambiguous leukemias that transcend current diagnostic boundaries. This article is highlighted in the In This Issue feature, p. 2659
Statin Use Associated with Lower Incidence of Developing Thyroid Eye Disease in Newly-Diagnosed Graves' Disease
Clark, Jennifer , Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | June 8, 2021 | Volume: 33 | Issue: 6 | Pages: 266-268

10.1089/ct.2021;33.266-268 Get It

Iodine Supplementation in Pregnant Women with Hashimoto's Thyroiditis
Thumma, Soumya, Maraka, Spyridoula

Mayo Clinic

Clinical Thyroidology | June 8, 2021 | Volume: 33 | Issue: 6 | Pages: 257-259

10.1089/ct.2021;33.257-259 Get It

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score
Gao, Chi , Polley, Eric C. , Hart, Steven N. , Huang, Hongyan , Lilyquist, Jenna , Boddicker, Nicholas , Na, Jie , Ambrosone, Christine B. , Auer, Paul L. , Gaudet, Mia M. , Haiman, Christopher A. , Jacobs, Eric J. , John, Esther M. , Lindström, Sara , Ma, Huiyan , Ong, Irene M. , Patel, Alpa V. , Taylor, Jack A. , Vachon, Celine M. , Weitzel, Jeffrey N. , Goldgar, David E. , Nathanson, Katherine L. , Chen, Chen , Hu, Chunling , Gnanaolivu, Rohan , Lilyquist, Jenna , Boddicker, Nicholas J , Na, Jie , Ambrosone, Christine B , Bernstein, Leslie , Burnside, Elizabeth S , Gaudet, Mia M , John, Esther M , Neuhausen, Susan L. , Newcomb, Polly A. , Ong, Irene M , Palmer, Julie R , Sandler, Dale P , Taylor, Jack A , Teras, Lauren R , Trentham-Dietz, Amy , Yao, Song , Weitzel, Jeffrey N , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Couch, Fergus J. , Kraft, Peter , Chen, C , Hart, Steven N , Polley, Eric C , Hu, Chunling , Bernstein, Leslie , Burnside, Elizabeth S. , Eliassen, A. Heather , Hunter, David J. , O’Brien, Katie M. , Olson, Janet E. , Palmer, Julie R. , Sandler, Dale P. , Tamimi, Rulla M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Weinberg, Clarice R. , Yao, Song , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Journal of Clinical Oncology | June 8, 2021 | Volume: 39 | Issue: 23 | Pages: 2564-2573

10.1200/jco.20.01992 | PMID 34101481 Get It

PURPOSE This study assessed the joint association of pathogenic variants (PVs) in breast cancer (BC) predisposition genes and polygenic risk scores (PRS) with BC in the general population. METHODS A total of 26,798 non-Hispanic white BC cases and 26,127 controls from predominately population-based studies in the Cancer Risk Estimates Related to Susceptibility consortium were evaluated for PVs in BRCA1, BRCA2, ATM, CHEK2, PALB2, BARD1, BRIP1, CDH1, and NF1. PRS based on 105 common variants were created using effect estimates from BC genome-wide association studies; the performance of an overall BC PRS and estrogen receptor–specific PRS were evaluated. The odds of BC based on the PVs and PRS were estimated using penalized logistic regression. The results were combined with age-specific incidence rates to estimate 5-year and lifetime absolute risks of BC across percentiles of PRS by PV status and first-degree family history of BC. RESULTS The estimated lifetime risks of BC among general-population noncarriers, based on 10th and 90th percentiles of PRS, were 9.1%-23.9% and 6.7%-18.2% for women with or without first-degree relatives with BC, respectively. Taking PRS into account, more than 95% of BRCA1, BRCA2, and PALB2 carriers had > 20% lifetime risks of BC, whereas, respectively, 52.5% and 69.7% of ATM and CHEK2 carriers without first-degree relatives with BC, and 78.8% and 89.9% of those with a first-degree relative with BC had > 20% risk. CONCLUSION PRS facilitates personalization of BC risk among carriers of PVs in predisposition genes. Incorporating PRS into BC risk estimation may help identify > 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent overscreening and enable more personalized risk management approaches.
Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids
Nicholson, Wanda K. , Parry, John Preston , Zhang, Shuaiqi , Laughlin‐Tommaso, Shannon K. , Jacoby, Vanessa L. , Anchan, Raymond M. , Venable, Sateria, Shiflett, Amber, Wegienka, Ganesa , Maxwell, G. Larry , Wojdyla, Daniel , Marsh, Erica E. , Laughlin-Tommaso, Shannon , Diamond, M P , Wallace, Kedra , Stewart, Elizabeth A. , Wise, Lauren Anne , Myers, Evan R.

Mayo Clinic

Journal of Women's Health | June 8, 2021 | Volume: 31 | Issue: 3 | Pages: 415-424

10.1089/jwh.2020.8915 | PMID 34101502 Get It

Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6–12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov ). Results: More than 26% ( n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6–12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score ( p < 0.001, p < 0.001), the total UF symptom QOL score ( p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale ( p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Waddell, Aaron , Liao, Daiqing , Waddell, Aaron R , Liao, Daiqing , Huang, Haojie

Mayo Clinic

Cancers | June 8, 2021 | Volume: 13 | Issue: 12 | Pages: 2872

10.3390/cancers13122872 | PMID 34201346 Get It

The CREB-binding protein (CBP) and p300 are two paralogous lysine acetyltransferases (KATs) that were discovered in the 1980s–1990s. Since their discovery, CBP/p300 have emerged as important regulatory proteins due to their ability to acetylate histone and non-histone proteins to modulate transcription. Work in the last 20 years has firmly established CBP/p300 as critical regulators for nuclear hormone signaling pathways, which drive tumor growth in several cancer types. Indeed, CBP/p300 are critical co-activators for the androgen receptor (AR) and estrogen receptor (ER) signaling in prostate and breast cancer, respectively. The AR and ER are stimulated by sex hormones and function as transcription factors to regulate genes involved in cell cycle progression, metabolism, and other cellular functions that contribute to oncogenesis. Recent structural studies of the AR/p300 and ER/p300 complexes have provided critical insights into the mechanism by which p300 interacts with and activates AR- and ER-mediated transcription. Breast and prostate cancer rank the first and forth respectively in cancer diagnoses worldwide and effective treatments are urgently needed. Recent efforts have identified specific and potent CBP/p300 inhibitors that target the acetyltransferase activity and the acetytllysine-binding bromodomain (BD) of CBP/p300. These compounds inhibit AR signaling and tumor growth in prostate cancer. CBP/p300 inhibitors may also be applicable for treating breast and other hormone-dependent cancers. Here we provide an in-depth account of the critical roles of CBP/p300 in regulating the AR and ER signaling pathways and discuss the potential of CBP/p300 inhibitors for treating prostate and breast cancer.
Senolytics reduce coronavirus-related mortality in old mice
Camell, Christina D. , Yousefzadeh, Matthew J. , Zhu, Yi , Prata, Larissa , Huggins, Matthew A. , Pierson, Mark , Zhang, Lei , O’Kelly, Ryan, Pirtskhalava, Tamar , Xun, Pengcheng , Ejima, Keisuke , Xue, Ailing, Tripathi, Utkarsh , Espíndola‐Netto, Jair Machado , Giorgadze, Nino, Atkinson, Elizabeth J. , Inman, Christina L., Johnson, Kurt O. , Cholensky, Stephanie H., Carlson, Timothy W. , O’Sullivan, M. Gerard , Jameson, Stephen C. , Meves, Alexander , Li, Ming , Prakash, Y. S. , Hamilton, Sara E. , Niedernhofer, Laura J. , Kirkland, James L. , Prata, Larissa G P Langhi , LeBrasseur, Nathan K , Khosla, Sundeep , O'Sullivan, M Gerard , Allison, David B , Jameson, Stephen C , Meves, Alexander , Prakash, Y S , Chiarella, Sergio E , Hamilton, Sara E , Tchkonia, T , Niedernhofer, Laura J , Kirkland, James L , Robbins, Paul D , Zhang, Lei , Zhu, Yi , O'Kelly, Ryan D., LeBrasseur, Nathan K. , Khosla, Sundeep , Allison, David B. , Chiarella, Sergio E. , Tchkonia, Tamar , Robbins, Paul D.

Mayo Clinic

Science | June 8, 2021 | Volume: 373 | Issue: 6552 | Pages: No page available

10.1126/science.abe4832 | PMID 34103349 Get It

Senescent cells exacerbate COVID-19 Cellular senescence is a state elicited in response to stress signals and is associated with a damaging secretory phenotype. The number of senescent cells increases with advanced age and this in turn drives age-related diseases. Camell et al. show that senescent cells have an amplified inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see the Perspective by Cox and Lord). This response is communicated to nonsenescent cells, suppressing viral defense mechanisms and increasing the expression of viral entry proteins. In old mice infected with a SARS-CoV-2–related virus, treatment with senolytics to reduce the senolytic cell burden reduced mortality and increased antiviral antibodies. Science , abe4832, this issue p. eabe4832 ; see also abi4474, p. 281
Are synthetic clinical notes useful for real natural language processing tasks: A case study on clinical entity recognition
Li, Jianfu , Zhou, Yujia , Jiang, Xiaoqian , Natarajan, Karthik , Pakhomov, Serguei , Xu, Hua , Xu, Hua , Jiang, Xiaoqian , Zhou, Yujia , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | June 8, 2021 | Volume: 28 | Issue: 10 | Pages: 2193-2201

10.1093/jamia/ocab112 | PMID 34272955 Get It

Abstract Objective : Developing clinical natural language processing systems often requires access to many clinical documents, which are not widely available to the public due to privacy and security concerns. To address this challenge, we propose to develop methods to generate synthetic clinical notes and evaluate their utility in real clinical natural language processing tasks. Materials and Methods : We implemented 4 state-of-the-art text generation models, namely CharRNN, SegGAN, GPT-2, and CTRL, to generate clinical text for the History and Present Illness section. We then manually annotated clinical entities for randomly selected 500 History and Present Illness notes generated from the best-performing algorithm. To compare the utility of natural and synthetic corpora, we trained named entity recognition (NER) models from all 3 corpora and evaluated their performance on 2 independent natural corpora. Results : Our evaluation shows GPT-2 achieved the best BLEU (bilingual evaluation understudy) score (with a BLEU-2 of 0.92). NER models trained on synthetic corpus generated by GPT-2 showed slightly better performance on 2 independent corpora: strict F1 scores of 0.709 and 0.748, respectively, when compared with the NER models trained on natural corpus (F1 scores of 0.706 and 0.737, respectively), indicating the good utility of synthetic corpora in clinical NER model development. In addition, we also demonstrated that an augmented method that combines both natural and synthetic corpora achieved better performance than that uses the natural corpus only. Conclusions : Recent advances in text generation have made it possible to generate synthetic clinical notes that could be useful for training NER models for information extraction from natural clinical notes, thus lowering the privacy concern and increasing data availability. Further investigation is needed to apply this technology to practice.
NAD+ deficit, protein acetylation and muscle aging
Ji, Li Li , Yeo, Dongwook

Mayo Clinic

Aging | June 7, 2021 | Volume: 13 | Issue: 11 | Pages: 14546-14548

10.18632/aging.203177 | PMID 34099589 Get It